Home > Result Summaries: Compounds > Haemophilus influenzae Type b, Meningococcal C-TT Conjugate Vaccine

Result Summaries: Haemophilus influenzae Type b, Meningococcal C-TT Conjugate Vaccine

Result Summaries for Haemophilus influenzae Type b, Meningococcal C-TT Conjugate Vaccine
GSK
Study ID		 Phase Title Summary (Download)
102547 Phase 3 Evaluate immunogenicity,safety & reactogenicity of a booster dose of Hib-MenC conjugate vaccine when given to healthy subjects aged 13-14 mths who were primed with 3 doses of Hib-MenC vs a booster dose of Infanrix hexa given to subjects primed with 3 doses of Infanrix hexa and Meningitec (1 citation(s)) Click here to download result summary.
103954 Phase 3 Evaluate safety,reactogenicity & immunogenicity of a booster dose of GSK Biologicals’ Hib-MenC given with Priorix™, vs Hib-MenC or Priorix™ only, in toddlers (13–14 m) primed with 3 doses of Hib (as part of a DTPa –containing vaccine) & MenC-CRM197 (1 citation(s)) Click here to download result summary.
103974 (primary study) Phase 3 Demonstrate non-inferiority of Men-C immune response of Hib-MenC with Infanrix™-IPV versus a licensed Men-C vaccine with Pediacel™ when given at 2, 3, 4 m and the immunogenicity of Hib-MenC when given as a booster dose at 12-15 m. (3 citation(s)) Click here to download result summary.
104056 Phase 3 Phase 3 open, controlled, multicenter, multicountry primary and booster vaccination study to demonstrate the non-inferiority of the meningoc serogroup C immune response of GSK Bios’ Hib-MenC vac co-admin with Infanrix™-IPV versus a licensed meningoc serogroup C vac co-admin with Pediacelib-MenC vac (1 citation(s)) Click here to download result summary.
106445 Phase 3 Study to demonstrate non-inferiority of GSK Biologicals’ Hib-MenC with Priorix™, versus MenC-CRM197 vaccine with Hiberix™ & Priorix™ in toddlers primed with Hib but not MenC & to evaluate persistence up to 5y after vaccination. (0 citation(s)) Click here to download result summary.
106672 Phase 3 Phase III Study to Assess Long-Term Persistence of a Booster Dose of GSK Biologicals' Hib-MenC vs a Booster Dose of Infanrix™ Hexa When Given to Subjects (14m) Primed in DTPa-HBV-IPV-097 & Boosted in Hib-MenC-TT-010 BST: DTPa-HBV-IPV-097 (1 citation(s)) Click here to download result summary.
109664 Phase 4 Assessment of long-term antibody persistence after a booster dose of GSK Biologicals’ Hib & meningococcal C vaccine (Menitorix™) 811936 given at 12-15 months of age to subjects primed with 3 doses of Menitorix™ at 2, 3, 4 months of age (1 citation(s)) Click here to download result summary.
110215 Phase 3 Immunogenicity & safety study in preterm & full-term infants of GSK Biologicals' Hib-MenC vaccine, Menitorix™ co-administered with Infanrix™ penta & Prevenar™ at 2, 4, 6 months & as a booster with Infanrix™ IPV & Prevenar™ at 16-18 months (0 citation(s)) Click here to download result summary.

Filter list by: